Cvac (cancer vaccine MUC-1) / Immutep, Sydys Corp - LARVOL DELTA

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - P2; N=350; Recruiting; Sponsor: Prima BioMed Ltd

Clinical • New P2 trial • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - P2; N=350; Recruiting; Sponsor: Prima BioMed Ltd; N=1000 ➔ 350

Clinical • Enrollment change • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - P2; N=91; Terminated; Sponsor: Prima BioMed Ltd; N=132 ➔ 91

Clinical • Enrollment change • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - P2; N=132; Terminated; Sponsor: Prima BioMed Ltd; N=286 ➔ 132; Trial primary completion date: Jul 2015 ➔ Feb 2015

Clinical • Enrollment change • Trial primary completion date • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - P2; N=132; Terminated; Sponsor: Prima BioMed Ltd; Recruiting ➔ Terminated; The study was terminated due to company restructuring and changes in drug development priorities.

Clinical • Trial termination • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - P2; N=350; Active, not recruiting; Sponsor: Prima BioMed Ltd; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - P2; N=286; Recruiting; Sponsor: Prima BioMed Ltd; Trial primary completion date: Dec 2016 ➔ Jul 2015

Clinical • Trial primary completion date • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - P2; N=350; Recruiting; Sponsor: Prima BioMed Ltd; Active, not recruiting ➔ Recruiting; Trial primary completion date: Dec 2016 ➔ Jul 2015

Clinical • Enrollment open • Trial primary completion date • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

$1.6 million R&D tax incentive refund received (Prima Biomed Press Release) - "Prima BioMed Ltd...is pleased to advise that it has received approximately $1.6 million in cash rebate from the Australian federal government's R&D tax incentive program. The cash rebate was provided essentially in respect of expenditure incurred on eligible Australian R&D activities conducted on the CVac clinical trials during the 2013 financial year."

Commercial • Ovarian Cancer

Ovarian cancer vaccine for patients who have progressed during the CAN-003 study (CAN-003X) (clinicaltrials.gov) - P2, N=15 -> 9; Sponsor: Prima BioMed; Active, not recruiting; Completion Date: Feb 2013 -> Oct 2013.

Trial completion date • Ovarian Cancer

Prima Biomed’s CVAC granted fast track designation by FDA (Prima Biomed Press Release) - "Prima BioMed Ltd...announce[d]...that the United States Food and Drug Administration (“FDA”) granted Fast Track Designation to the CVac clinical development program at Prima.This program is intended to improve overall survival in patients with relapsed platinum-sensitive epithelial ovarian cancer who enter a second complete remission."

Fast track designation • Ovarian Cancer

Conference Call (Immutep) - "Promising trend in PFS data; Median PFS (as of Aug 2012), NR Cvac: 421 D, Cvac: 365 D, Control: 321 D"

P2 data • Ovarian Cancer